GlassScriptPhysician profile
Jason J Wang
NPI 1275514937
$4,537.64
in general payments reported to CMS, 2019-2025
17 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $172 · 2021: $278 · 2022: $797 · 2023: $261 · 2024: $1,401 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,109 · Travel and Lodging: $649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,108.96 |
| Travel and Lodging | $649.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,817.54 | 2019-2025 | Clareon, Clareon Panoptix Pro, Tryptyr |
| Johnson & Johnson Surgical Vision, INC. | $411.32 | 2019-2025 | Tecnis Simplicity |
| Glaukos Corporation | $285.95 | 2021-2022 | |
| Carl Zeiss Meditec USA, INC. | $203.47 | 2022-2025 | |
| Rxsight INC | $177.96 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $147.05 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $138.23 | 2022-2023 | Lotemax Sm, Miebo |
| Novartis Pharmaceuticals Corporation | $122.35 | 2019-2023 | |
| Staar Surgical Company | $61.49 | 2019 | |
| Kala Pharmaceuticals, INC. | $34.99 | 2019-2020 | |
| Allergan, INC. | $31.40 | 2019-2021 | |
| Abbvie INC. | $21.68 | 2025 | |
| Heidelberg Engineering, INC. | $18.86 | 2024 | Spectralis |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Thea Pharma INC. | $16.84 | 2025 | Iyuzeh |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $15.83 | 2021 | |
| Halozyme INC | $15.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.